Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Blood Rev. 2023 Nov;62:101035. doi: 10.1016/j.blre.2022.101035. Epub 2022 Nov 15.
Haploidentical donor stem cell transplantation (haplo-SCT) has made great advances in recent decades. The granulocyte colony-stimulating factor (G-CSF)- and antithymocyte globulin (ATG)-based protocol, which is known as the Beijing Protocol, represents one of the current T-cell repletion strategies in haplo-SCT. The key elements of the Beijing Protocol for graft versus host disease (GvHD) prophylaxis include G-CSF inducing T-cell tolerance and altering graft cell components, as well as ATG administration exerting an immunoregulatory effect for intensive prophylaxis. This review will summarize the GvHD incidence, the underlying novel mechanism for GvHD prophylaxis, how to optimize GvHD prophylaxis, and the recent advances of the Beijing Protocol, mainly focusing on the issues of GvHD.
近年来，单倍体供者造血干细胞移植（haplo-SCT）取得了重大进展。基于粒细胞集落刺激因子（G-CSF）和抗胸腺细胞球蛋白（ATG）的方案，即所谓的北京方案，代表了haplo-SCT 中目前的 T 细胞再填充策略之一。北京方案预防移植物抗宿主病（GvHD）的关键要素包括 G-CSF 诱导 T 细胞耐受和改变移植物细胞成分，以及 ATG 给药发挥免疫调节作用进行强化预防。这篇综述将总结 GvHD 的发生率、GvHD 预防的新机制、如何优化 GvHD 的预防，以及北京方案的最新进展，主要集中在 GvHD 方面的问题。
